Stifel resumed coverage of Nuvalent (NUVL) with a Buy rating and $115 price target Nuvalent has “two of the highest quality drugs in targeted oncology,” which will be broadly used once approved, the analyst tells investors. The firm models first commercial revenue in the second half of 2026, with about $2.9B in global revenue by 2035, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Cantor starts Nuvalent at Overweight, sees 60% potential upside
- Nuvalent initiated with an Overweight at Cantor Fitzgerald
- Nuvalent’s Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potential
- Nuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
- Nuvalent Completes New Drug Application Submission